NASDAQConsumer StaplesPackaged FoodsSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for NAII yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Cash from operating activities improves to positive | A primary condition in Natural Alternatives International Inc's published investment case. The stated target is >= $2.5M. | Broken | cash from operating activities falls below $0 | Cash from operations: $6.302M FY2025-Q4; GAAP. Published target: >= $2.5M. The stored target says 2026-Q3; this source reports FY2025-Q4. Fiscal/calendar alignment needs review. Sep 28, 20266,302,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
Comparable estimate history is unavailable.
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Compare required revenue and earningsMonthly analyst history is unavailable.
Recent actions · Oct 6–Nov 4 · 0 recorded
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 11, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a speculative turnaround, meaning the thesis depends on the business improving from a weak starting point. The current thesis state is watch: the signal has shifted from cautious to mixed, but recent performance remains well below its industry cohort.
The valuation evidence points to NAII being cheap versus peers, while the model confidence is low. The expectations gap is negative, but the evidence does not explain its scale; the priced-in tag is justified and fragility is low.
Near term, operating cash flow improved from negative in the second quarter of 2026 to positive in the third, but net losses widened and gross profit fell sharply. Management has kept cash flow, profitability, and margins as priorities, yet recent results show uneven progress and the next earnings report carries elevated miss risk.
Over the next year, the thesis hinges on whether cash flow gains continue and losses and margin pressure ease. A guidance cut or further labor-market weakening would add pressure, while continued strong results and higher guidance from sector peers could support the sector backdrop.
For the 1-to-3-year view, NAII remains a fragile recovery story rather than a demonstrated return to profitability. The key evidence to watch is whether improved operating cash flow turns into sustained progress on earnings and margins. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated in 3 of last 3 quarters. Cash from operating activities improved from -$6.33M in 2026-Q2 to $2.50M in 2026-Q3, indicating progress towards stabilizing financial performance. The trajectory shows delivering on this priority.
Gross profit improves from recent lows | A supporting condition in Natural Alternatives International Inc's published investment case. The stated target is gross profit >= $0.38M. | Intact | gross profit falls below $0.3M | Gross profit: $383,000 FY2026-Q3; GAAP. Published target: gross profit >= $0.38M. The target does not explicitly identify fiscal versus calendar quarters. May 19, 2026383,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 3 of last 3 quarters. Gross profit decreased from $2.49M in 2026-Q2 to $0.38M in 2026-Q3, showing limited progress in enhancing margins. The trajectory indicates challenges in achieving this priority. Delivery assessment Jul 30, 2026 |
Net income moves toward profitability | A primary condition in Natural Alternatives International Inc's published investment case. The stated target is net income improves toward >= $0. | Broken | net income worsens or stays below -$4M | Net income: $-4.311M FY2026-Q3; GAAP. Published target: net income improves toward >= $0. Target period is not explicitly aligned with this observation. May 19, 2026-4,311,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 3 of last 3 quarters. Despite efforts, net income declined from -$2.55M in 2026-Q2 to -$4.31M in 2026-Q3, indicating limited progress towards profitability. The trajectory shows challenges in achieving this priority. Delivery assessment Jul 30, 2026 |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.